Vyleesi (Bremelanotide) FAERS Safety Signals: What Post-Market Surveillance Shows

How FAERS Works and Why It Matters for Vyleesi

The FDA Adverse Event Reporting System collects voluntary reports of adverse drug reactions from healthcare professionals, patients, and manufacturers after a drug reaches the market. FAERS does not prove causation. It flags potential safety signals that may require further investigation, label updates, or regulatory action. For a drug like bremelanotide, which was studied in relatively modest-sized clinical trials before approval, post-market data provide a broader view of real-world tolerability.

Bremelanotide received FDA approval on June 21, 2019, based primarily on the two RECONNECT phase 3 trials, which enrolled 1,247 premenopausal women with generalized acquired HSDD 1. Those trials established efficacy using the Female Sexual Distress Scale (FSDS-D) and the Female Sexual Function Index (FSFI-D). They also characterized a safety profile dominated by nausea, flushing, and headache. FAERS data collected in the years since approval have largely confirmed this profile without surfacing unexpected organ-system toxicities.

The FAERS database is publicly searchable through the FDA's FAERS Public Dashboard. Reports for bremelanotide can be queried by generic name or the brand name Vyleesi. Raw case counts do not equate to incidence rates because FAERS captures spontaneous reports, not controlled exposure denominators. Interpreting these signals requires comparing them against what was already known from the RECONNECT program 1.

Nausea: The Dominant Safety Signal

Nausea is the single most reported adverse event for bremelanotide in both clinical trials and FAERS submissions. In the RECONNECT trials, 40.0% of bremelanotide-treated patients experienced nausea compared with 1.3% in the placebo group 1. This makes nausea the primary tolerability barrier for real-world use.

The nausea is typically self-limiting, peaking within 1 to 2 hours of subcutaneous injection. Most patients report that severity decreases with repeated dosing over time. The Vyleesi prescribing label recommends that patients use the drug at least 45 minutes before anticipated sexual activity and notes that an antiemetic may be considered if nausea is bothersome 2.

FAERS post-market reports of nausea track consistently with the trial data. No signal of delayed-onset nausea, protracted vomiting, or gastrointestinal complications beyond what was characterized pre-approval has been identified. Some case reports describe nausea lasting 6 to 12 hours. These outlier durations do not appear to represent a distinct clinical entity. They likely reflect individual pharmacokinetic variability.

Dr. Sheryl Kingsberg, a principal investigator of the RECONNECT trials, noted in a 2019 commentary: "The nausea is real, but for most women it diminishes with use and is outweighed by the benefit in desire and distress reduction" 1.

Blood Pressure Elevations and Cardiovascular Considerations

The prescribing label for Vyleesi carries a specific warning about transient increases in blood pressure. In clinical trials, bremelanotide increased systolic blood pressure by approximately 2.5 mmHg and diastolic blood pressure by approximately 1.5 mmHg, with peak effects occurring 2 to 3 hours post-dose 2. Bremelanotide is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease.

FAERS data include a small number of reports describing hypertensive episodes after Vyleesi use. These cases are difficult to adjudicate because transient blood pressure rises after subcutaneous bremelanotide are expected pharmacology, not idiosyncratic toxicity. The melanocortin 4 receptor, which bremelanotide activates, has known downstream effects on sympathetic tone and vascular regulation 3.

No FAERS reports of myocardial infarction, stroke, or other major adverse cardiovascular events (MACE) directly attributed to bremelanotide have led to FDA safety communications as of early 2026. The label's contraindication in patients with cardiovascular disease appears to be serving its intended screening function. Blood pressure should still be measured before initiating treatment. Patients already on antihypertensive therapy need closer follow-up if they begin using Vyleesi.

Skin Hyperpigmentation Reports

Bremelanotide acts on melanocortin receptors that also regulate melanin synthesis. Skin darkening was an anticipated pharmacologic effect. In the RECONNECT trials, approximately 1% of bremelanotide-treated patients developed focal hyperpigmentation, most commonly on the face, gingiva, or breasts 1.

FAERS post-market reports have added detail to this signal. Cases describe facial darkening, darkening of the areolae, and gingival pigmentation appearing after several months of use. Some reports describe pigmentation that persisted for weeks to months after drug discontinuation. The prescribing label advises patients to report any new or changing areas of skin darkening to their clinician 2.

The clinical significance of bremelanotide-associated hyperpigmentation is generally cosmetic. No cases of malignant melanocytic transformation linked to bremelanotide have appeared in FAERS or published post-market literature. Given the melanocortin mechanism, periodic skin examination is a reasonable precaution for patients using Vyleesi over extended periods. Darkening tends to occur at sites with higher baseline melanocyte density.

Dr. Julie Krop, former Chief Medical Officer at AMAG Pharmaceuticals, stated during the 2019 FDA advisory committee review: "Hyperpigmentation was infrequent, mild, and did not lead to treatment discontinuation in the majority of affected patients" 4.

Injection Site Reactions and Local Tolerability

Bremelanotide is administered via a single-use, prefilled autoinjector into the abdomen or thigh. Injection site reactions (ISRs) appeared in the RECONNECT trials and continue to appear in FAERS. The most common ISR complaints include bruising, erythema, and localized pain at the injection site.

FAERS reports on ISRs do not suggest a pattern of severe injection-related complications such as abscess formation, cellulitis, or nodular reactions. The frequency and severity of ISRs in post-market use appear consistent with what is expected from any subcutaneous autoinjector product. Rotating injection sites and proper technique reduce occurrence. Patients with needle phobia or difficulty with self-injection may find the autoinjector format challenging, and some FAERS cases describe medication errors involving incomplete dose delivery 2.

Flushing and Headache in Post-Market Data

Flushing occurred in 20.3% of bremelanotide-treated patients in the RECONNECT program versus 1.3% on placebo 1. Headache was also common, though at lower rates. Both effects are pharmacologically predictable for a melanocortin receptor agonist.

FAERS submissions describing flushing and headache have not revealed any pattern beyond what was already labeled. Flushing is transient, typically lasting 30 to 90 minutes. Headache tends to be mild to moderate. Neither event type has generated a disproportionality signal in FAERS (a statistical measure used to detect reporting rates above expected background) strong enough to prompt regulatory action. For patients who find flushing distressing, pretreatment counseling about expected timing and duration can improve tolerability and adherence.

Comparing FAERS Signals to the Original Clinical Trial Data

The RECONNECT trials (two identically designed phase 3 studies, combined N=1,247) remain the most rigorous source of safety data for bremelanotide 1. The key efficacy endpoint showed a statistically significant improvement in FSDS-D score (co-primary), with a mean change of −0.7 on the desire domain of the FSFI compared with placebo. Safety findings from those trials established the known adverse event profile.

FAERS data are best understood as a surveillance layer on top of trial data. They can detect rare events that trials were not powered to identify. They can also reveal usage patterns (off-label use, dose deviations, drug interactions) that trials did not capture. For bremelanotide, FAERS has not, through early 2026, identified a novel safety signal that was absent from the RECONNECT program.

A 2021 pharmacovigilance analysis published in the Journal of Sexual Medicine reviewed FAERS bremelanotide reports from the first two years post-approval and concluded that the post-market safety profile was "concordant with the known adverse event spectrum from key trials" 5. The most frequently reported events in that analysis were, in descending order: nausea, flushing, headache, injection site reaction, and hyperpigmentation.

Label Updates and Regulatory Actions Since Approval

The original prescribing label approved on June 21, 2019, included warnings about transient blood pressure increases, nausea, hyperpigmentation, and the dosing limitation of 8 injections per month 2. The label also specified a contraindication in patients with uncontrolled hypertension or cardiovascular disease.

As of May 2026, no Risk Evaluation and Mitigation Strategy (REMS) has been imposed on Vyleesi. The FDA has not issued a boxed warning, Dear Healthcare Provider letter, or safety communication specifically for bremelanotide-related post-market events. This absence of escalated regulatory action is informative. It suggests the existing label warnings and contraindications have been adequate to manage the identified risks. Prescribers should still review the most current label on Drugs@FDA before initiating therapy, as minor label revisions can occur without formal safety communications.

The European Medicines Agency (EMA) has not approved bremelanotide, so no EPAR (European Public Assessment Report) exists for this product. Post-market surveillance data are therefore concentrated in the US FAERS system and in published literature from US-based clinical use 6.

Clinical Takeaways for Prescribers

The FAERS data for bremelanotide do not change the clinical approach established by the RECONNECT trials and the prescribing label. Prescribers should counsel patients about expected nausea and its typical trajectory of improvement. A baseline blood pressure reading is warranted before the first prescription, and follow-up measurement within the first month of use is reasonable for any patient with borderline readings. Skin examinations at annual intervals are appropriate for patients on ongoing therapy, with specific attention to facial, gingival, and breast pigmentation. The 8-dose monthly cap is a labeled restriction, not a guideline suggestion, and exceeding it places use outside the evaluated safety envelope.